Clinical trial condition

MSI-H

Explore clinical trials studying MSI-H. Study availability and eligibility vary by location and protocol.

7 public trials 4 recruiting studies

Refine in advanced search Browse all conditions

MSI-H trial results

Recruiting

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

NCT06346197

Conditions: Advanced Cancer, Digestive System Diseases, Digestive System Neoplasms, +13 more
Locations: CHU de Brest Brest, France

CHU de Clermont-Ferrand Clermont-Ferrand, France

Centre Léon Bérard Lyon, France

Hôpital Privé Jean Mermoz Lyon, France

View Trial Details

Recruiting

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

NCT06580574

Conditions: Colon Cancer, Colonic Diseases, Colonic Neoplasms, +14 more
Locations: Beijing Cancer Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

NCT07001592

Conditions: DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, +27 more
Locations: AHN West Penn Hospital Pittsburgh, Pennsylvania, United States

View Trial Details

Recruiting

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

NCT04636008

Conditions: Anti-PD-1 Antibody, Colorectal Neoplasms, Digestive System Diseases, +14 more
Locations: West China Hospital of Sichuan University Chengdu, Sichuan, China

View Trial Details

Completed

Study of the CD40 Agonistic Monoclonal Antibody APX005M

NCT02482168

Conditions: Cancer, Carcinoma, Carcinoma, Transitional Cell, +18 more
Locations: City of Hope Duarte, California, United States

Case Western Reserve University Cleveland, Ohio, United States

Abramson Cancer Center of The University of Pennsylvania Philadelphia, Pennsylvania, United States

View Trial Details

Completed

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

NCT03775850

Conditions: Adenocarcinoma, Bladder Cancer, Breast Diseases, +35 more
Locations: Highlands Oncology Group Rogers, Arkansas, United States

Florida Cancer Specialists Sarasota, Florida, United States

Stephenson Cancer Center Oklahoma City, Oklahoma, United States

Tennessee Oncology, PLLC Chattanooga, Tennessee, United States

View Trial Details

Active, Not Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

NCT05890742

Conditions: MSI-H
Locations: Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

View Trial Details

MSI-H

MSI-H trial results

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Related conditions